We have studied the
leukotriene antagonistic activity of a novel compound,
SR2640 (2-[3-(2-quinolylmethoxy)phenylamino]
benzoic acid), in vitro and in vivo.
SR2640 inhibited LTD4- but not
histamine-induced contractions of guinea-pig ileum and trachea in a concentration-dependent manner. Schild plot analysis of tracheal
LTD4 antagonism yielded a pA2 value of 8.7 and a slope not different from unity.
SR2640 concentration dependently inhibited the binding of 0.4 nM [3H]
LTD4 to guinea-pig lung membranes with an IC50 value of 23 nM. The curve was parallel to that of unlabelled
LTD4 (IC50 = 2.2 nM).
SR2640 was equally effective in antagonizing
LTD4 and
LTE4, but was much less potent in reducing LTC4-induced ileum contractions. In vivo,
SR2640 in the dose range 0.03-1.00 mg/kg shifted the dose-response curve for guinea-pig bronchoconstriction induced by intravenous
LTD4 administration to the right at a rate proportional to the dose of
SR2640, without reducing the maximum attainable obstruction: the slope of the Schild plot was 0.99.
SR2640 (1 mg/kg) also caused a significant inhibition of
antigen-induced bronchoconstriction in anaesthetized guinea-pigs pretreated with
pyrilamine,
indomethacin,
propranolol and
suxamethonium. In conclusion,
SR2640 appears to be a potent and selective competitive
LTD4/
LTE4 antagonist, and may be useful in elucidating the role of
leukotrienes in human
asthma.